kneat.com (KSI) AI Stock Analysis

• Market Cap: C$485.26M
• Dividend Yield: N/A
• Average Volume (3M): 120.08K
• Price to Earnings (P/E): 942.6
• Beta (1Y): 1.12
• Revenue Growth: 33.27%
• EPS Growth: 86.18%
• Country: CA
• Employees: 297
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 95,336,075
• 10 Day Avg. Volume: 105,937
• 30 Day Avg. Volume: 120,085
• PEG Ratio: 1.30
• Price to Book (P/B): 7.79
• Price to Sales (P/S): 10.36
• P/FCF Ratio: -50.25
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$6.33
• Price Target Upside: 42.25% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: C$4.50 ▲(1.12% Upside)

The overall stock score is primarily influenced by the company's strong revenue growth and high customer satisfaction, as highlighted in the earnings call. However, significant profitability challenges, bearish technical indicators, and a negative P/E ratio weigh heavily on the score. The company needs to improve its profitability and cash flow generation to enhance its financial position.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust market demand and effective sales strategies, supporting long-term business expansion and market position.

High Customer Satisfaction

High customer satisfaction reflects strong product quality and service, enhancing brand loyalty and competitive advantage in the market.

Strategic R&D Investments

Ongoing R&D investments ensure innovation and product improvement, maintaining competitive edge and market leadership in the long term.

Negative Factors

Profitability Challenges

Negative profit margins indicate ongoing profitability issues, which may hinder financial stability and growth potential if not addressed.

Increased Operating Expenses

Rising operating expenses can strain profitability and cash flow, requiring efficient cost management to sustain long-term financial health.

Competitive Pressures

Heightened competition may pressure market share and pricing power, necessitating strategic differentiation to maintain competitive advantage.

kneat.com Business Overview & Revenue Model

Company Description

kneat.com, inc. designs, develops, and supplies software for data and document management within regulated environments in the United States, Ireland, Canada, and internationally. The company offers Kneat Gx platform, a configurable commercial off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries. Its platform is used in process, computer system, cleaning, analytical instrument, method, utility and facility, equipment, and cold chain validation, as well commissioning and qualification, and electronic logbook management. The company also provides software-related services, including training, installation, upgradation, consulting, and maintenance, as well as process mapping, project management, and other services. kneat.com, inc. is headquartered in Limerick, Ireland.

How the Company Makes Money

Kneat.com generates revenue primarily through a subscription-based model, where clients pay for access to its software solutions on a recurring basis. This includes annual licensing fees for the Kneat GxP platform, which vary based on the scale of implementation and the number of users. Additionally, the company earns revenue from professional services, which can include implementation support, training, and consulting services to help clients optimize their use of the software. Key partnerships with industry leaders and regulatory bodies also enhance Kneat's credibility and market reach, contributing to its earnings by attracting a larger client base seeking reliable compliance solutions.

kneat.com Financial Statement Overview

Summary

Kneat.com demonstrates strong revenue growth and a solid gross profit margin, indicating effective cost management. However, profitability remains a concern with negative net profit margins. The balance sheet shows improved leverage and a strong equity base, but returns on equity are low. Cash flow generation is improving, but free cash flow remains negative. Overall, the company is on a positive trajectory but needs to enhance profitability and cash flow generation to strengthen its financial position.

Income Statement

The company has shown a strong revenue growth rate of 7.05% in the TTM period, indicating positive momentum. Gross profit margin remains robust at 75.11%, reflecting efficient cost management. However, the net profit margin is negative at -4.24%, highlighting profitability challenges. The EBIT margin is slightly positive at 3.10%, but the company needs to improve its operational efficiency to enhance profitability.

Balance Sheet

The debt-to-equity ratio has improved to 0.37 in the TTM period, indicating a more balanced capital structure. Return on equity is low at 0.83%, suggesting limited returns for shareholders. The equity ratio stands at 49.29%, showing a solid equity base. Overall, the balance sheet reflects moderate financial stability with room for improvement in profitability.

Cash Flow

Operating cash flow has improved significantly, with a positive operating cash flow to net income ratio of 0.41. However, free cash flow remains negative, although it has shown substantial growth. The free cash flow to net income ratio is negative, indicating challenges in generating free cash flow relative to net income. The company needs to focus on improving cash flow generation to support growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.65M	48.94M	34.22M	23.75M	15.50M	7.42M
Gross Profit	42.68M	36.76M	23.13M	14.65M	9.32M	2.88M
EBITDA	16.02M	6.27M	-5.37M	-3.20M	-5.11M	-2.30M
Net Income	476.72K	-7.73M	-14.12M	-9.15M	-9.86M	-5.88M
Balance Sheet
Total Assets	134.67M	124.58M	64.50M	50.41M	51.28M	33.80M
Cash, Cash Equivalents and Short-Term Investments	66.77M	58.89M	15.25M	12.28M	21.56M	8.66M
Total Debt	30.66M	29.26M	28.17M	7.09M	7.86M	9.52M
Total Liabilities	68.29M	59.51M	49.73M	24.43M	17.09M	14.59M
Stockholders Equity	66.38M	65.07M	14.76M	25.98M	34.19M	19.21M
Cash Flow
Free Cash Flow	-5.54M	-10.09M	-18.39M	-9.82M	-7.74M	-9.28M
Operating Cash Flow	15.31M	9.79M	-1.28M	2.99M	2.31M	-1.98M
Investing Cash Flow	-18.94M	-17.52M	-15.97M	-11.91M	-10.04M	-6.43M
Financing Cash Flow	30.23M	50.62M	20.27M	-383.91K	21.20M	13.11M

kneat.com Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KSI, the sentiment is Negative. The current price of 4.45 is below the 20-day moving average (MA) of 4.53, below the 50-day MA of 5.22, and below the 200-day MA of 5.87, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 41.60 is Neutral, neither overbought nor oversold. The STOCH value of 76.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KSI.

kneat.com Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VHI	65 Neutral	C$637.25M	113.06	1.45%	―	59.34%	-23.48%
KSI	53 Neutral	C$485.26M	942.59	-2.45%	―	33.27%	86.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADK	44 Neutral	C$32.09M	-6.38	―	―	-48.53%	-9.66%
AIML	38 Underperform	C$12.70M	-1.47	-1143.80%	―	-64.23%	18.42%
UDOC	34 Underperform	$12.98M	―	―	―	―	21.61%
AIDR	34 Underperform	C$68.33M	-5.19	-202.19%	―	―	40.17%

kneat.com Corporate Events

Kneat.com, Inc. Reports Strong SaaS Growth Amid Challenges

Kneat.com, Inc. recently held its earnings call, revealing a generally positive sentiment driven by robust growth in SaaS revenue and high customer satisfaction. The company emphasized its strategic investments in research and development (R&D) as a key factor in maintaining its competitive edge. However, concerns were raised regarding the significant rise in operating expenses and the challenges posed by macroeconomic factors and competitive pressures.

Kneat to Release Q3 2025 Financial Results

Kneat.com announced it will release its third-quarter financial results for 2025 on November 12, following the close of the TSX market. The announcement highlights Kneat’s continued focus on transparency and engagement with stakeholders, as the company plans a webcast conference call for analysts the following day. This release is part of Kneat’s ongoing efforts to maintain its leadership in the digital validation industry, providing stakeholders with insights into its financial performance and strategic direction.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$6.00 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat Secures Major Agreement to Enhance Digital Transformation for Global Manufacturer

Kneat.com has entered into a Master Services Agreement with a leading multinational manufacturer to implement its Kneat Gx platform for digital transformation across enterprise applications and manufacturing sites. This strategic partnership underscores Kneat’s ability to enhance compliance, efficiency, and scalability in validation processes, further solidifying its position as a preferred platform in the life sciences sector.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat.com Leads G2 Pharma and Biotech Software Rankings

Kneat.com has been recognized as a leader in G2’s Fall 2025 Pharma and Biotech Software category reports, achieving top positions in three categories. The company’s high G2 Satisfaction Score of 98 reflects strong customer satisfaction and market presence, highlighting its impact in the life sciences industry.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat Solutions to Showcase Innovations at Emerging Growth Conference

Kneat Solutions announced its participation in the Emerging Growth Conference on September 24, 2025, where CEO Eddie Ryan will present the company’s recent progress and engage with investors in a live, interactive session. This event highlights Kneat’s ongoing commitment to innovation in digital validation, reinforcing its position as a key player in the life sciences industry by providing solutions that reduce risk and accelerate product market entry.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat Secures Strategic Agreement with Leading Equipment Manufacturer

Kneat.com has secured a three-year Master Services Agreement with a major European equipment manufacturer, marking its seventh strategic customer win in 2025. This agreement will see the implementation of the Kneat Gx platform to digitize the manufacturer’s equipment testing processes, enhancing quality and client handover, and is part of Kneat’s ongoing success in expanding digital capabilities across industries.

The most recent analyst rating on (TSE:KSI) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.